

HSCT long-term survivors,⁷ among many other patient populations. Although PROMIS fulfills many PRO metrics, it is important to note that it, as well as many HRQOL measures, does not assess specific sociobehavioral and environmental domains such as occupational, financial, and health behavior concerns. Although PROs do exist to address these domains, there are no uniform validated measures within the HSCT and cancer survivorship populations. Because of the availability of numerous tools to assess PROs and HRQOL, harmonization of metrics from various tools is essential for interpreting results across studies in order to identify optimal survivorship care practices.

Second, challenges related to the feasibility of standard longitudinal collection of PROs must be addressed, as there remains significant heterogeneity in the use and timing of symptom assessments. All patients with cancer face challenging transitions in care as they complete initial therapy and shift to long-term follow-up, a situation only accentuated among HSCT recipients, who may be followed by their transplant center, primary oncologist, or primary cancer physician. Although it is important to account for the survey burden that patients may face in participating in potentially frequent PRO measurement, the Center for International Blood and Marrow Transplant Research (CIBMTR) has established feasibility of routine longitudinal PRO assessment, with initial recruitment by the transplant center and then centralized posttransplant PRO collection through the CIBMTR.⁸ Further work is ongoing to implement the standard collection of longitudinal PROs through the CIBMTR to be able to correlate PROs with clinical outcomes data. However, the optimal timing of PRO collection may depend on the specific patient population.

Despite the challenges in adopting PROs into research trials and standard clinical practice, the results from Yen and colleagues demonstrate the importance of PROs for illuminating the substantial burdens carried by adult survivors of pediatric hematologic malignancy. Particularly for patient populations with substantial long-term morbidity, such as HSCT recipients and pediatric cancer survivors, the widespread and consistent use of longitudinal PROs will be an essential tool for further understanding and improving survivorship care.

Conflict-of-interest disclosure: The authors declare no competing financial interests. ■

REFERENCES

1. Yen H-J, Eissa HM, Bhatt NS, et al. Patient-reported outcomes in survivors of childhood hematologic malignancies with hematopoietic stem cell transplant. *Blood*. 2020;135(21):1847-1858.
2. Palmer J, Chai X, Pidala J, et al. Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. *Blood*. 2016;127(1):160-166.
3. Mierzynska J, Piccinin C, Pe M, et al. Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review. *Lancet Oncol*. 2019;20(12):e685-e698.
4. Powell ND, Sloan EK, Bailey MT, et al. Social stress up-regulates inflammatory gene expression in the leukocyte transcriptome via

β -adrenergic induction of myelopoiesis. *Proc Natl Acad Sci USA*. 2013;110(41):16574-16579.

5. Knight JM, Rizzo JD, Logan BR, et al. Low socioeconomic status, adverse gene expression profiles, and clinical outcomes in hematopoietic stem cell transplant recipients. *Clin Cancer Res*. 2016;22(1):69-78.
6. Knight JM, Rizzo JD, Hari P, et al. Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. *Blood Adv*. 2020;4(3):467-476.
7. Lee SJ, Onstad L, Chow EJ, et al. Patient-reported outcomes and health status associated with chronic graft-versus-host disease. *Haematologica*. 2018;103(9):1535-1541.
8. Shaw BE, Brazauskas R, Millard HR, et al. Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful. *Cancer*. 2017;123(23):4687-4700.

DOI 10.1182/blood.202005881

LYMPHOID NEOPLASIA

Comment on Condoluci et al, page 1859


A predictive tool for early-stage CLL

Constantine S. Tam and John F. Seymour | Peter MacCallum Cancer Centre; University of Melbourne; The Royal Melbourne Hospital

In this issue of *Blood*, Condoluci et al report that, using a large international cohort of 4933 patients from 11 groups, they have developed an international prognostic score (IPS-E) for predicting time to first treatment (TTFT) in patients with asymptomatic, early-stage CLL.¹ Although there have been multiple past publications on prognostication in CLL, previous models have predominantly addressed overall survival as the end point of interest.² Although survival is obviously of interest for both physicians and patients, the long survival duration of patients with early-stage CLL³ means that a more immediately relevant and often asked question is: "Doctor, how long do I have before I have to put my life on hold and accept treatment for my leukemia?"

To answer this question, Condoluci et al examined features associated with TTFT in a training set of 333 consecutive patients followed over a median of 7.2 years at the University of Eastern Piedmont.¹ This cohort was remarkably complete in terms of biological information, with immunoglobulin HV (IgHV) mutation, fluorescence in situ hybridization, and *TP53* mutational status known in all patients. Using a multivariable model, 3 factors of equal weighting (1 point each) were identified to be independently predictive of TTFT: unmutated IgHV status, lymphocyte count higher than $15 \times 10^9/L$, and palpable nodes. Successful validation of these factors

in 10 other European and US cohorts led to establishment of the IPS-E, which divided patients into approximately thirds: patients with score 0 (30%) have a low risk of requiring treatment (2.0 per 100 person-years), score 1 (36%) yields an intermediate risk of requiring treatment (6.1 per 100 person-years), and score 2 to 3 (34%) indicates a high risk of requiring treatment (16.1 per 100 person-years). Importantly, although *TP53* deletions/mutations are key determinants of treatment response and overall survival after commencement of therapy, in this study, *TP53* aberrations are not found to be independently predictive of TTFT



IPS-E stratified time to first treatment in early stage CLL patients managed with active surveillance. (A) Kaplan-Meier curves of TTFT stratified by IPS-E in the University of Eastern Piedmont discovery cohort. (B) Meta-analytic estimate of TTFT by IPS-E and the corresponding variability across the 9 Binet A validation cohorts. The bold line shows the cubic spline fitted on the meta-analytic estimate of the cumulative proportion of TTFT at each timepoint. The shadow shows the cubic splines fitted on the meta-analytic estimate of the 95% confidence interval of the cumulative proportion of TTFT at each timepoint. (C) Kaplan-Meier curves of time to first treatment stratified by IPS-E in the Mayo Clinic validation cohort. Blue, low-risk; green, intermediate-risk; red, high-risk by IPS-E. Multiplicity corrected *P* values by pairwise log-rank tests are shown. See Figure 2 in the article by Condoluci et al that begins on page 1859.

in otherwise asymptomatic patients. This observation confirms previous reports that *TP53* aberrant CLL can behave in an indolent manner when accompanied by favorable biological risk factors such as mutated IgHV,^{4,5} thus underscoring the importance of not managing early-stage patients differently solely on the basis of *TP53* status.

Overall, the IPS-E is a simple tool that has immediate relevance to the clinician counseling newly diagnosed patients in the clinic. However, it does depend crucially on IgHV mutation testing, which is not considered an essential test at diagnosis by the current IWCLL guidelines,⁶ and there remain many areas of the world where IgHV mutation testing is not performed by community physicians practicing outside of academic centers. As an example, in the current study, comprising patients enrolled predominantly from specialist CLL research groups, IgHV status is known in all but 15 of the 4933 patients. In contrast, data from the real-world InformCLL registry showed

that testing for IgHV mutation status occurred in only 11% of patients managed in the US community setting.⁷ In contrast, fluorescence in situ hybridization and sequencing tests for *TP53* deletions and mutations are not required at diagnosis, but should be checked before therapy, as *TP53* status significantly influences the choice of treatment.^{6,8}

Finally, it is important to remember that outside of the clinical trial setting, treatment of CLL is not indicated until the development of symptomatic disease meeting published criteria.^{6,8} Phase 3 studies of FCR vs watch and wait⁹ and ibrutinib vs placebo¹⁰ have yet to show overall survival benefit for early intervention in any risk group. The IPS-E is a shiny new tool for risk stratifying patients in the clinic; however, good clinical judgement and adherence to clinical guidelines remain the cornerstones of modern CLL management.

Conflict-of-interest disclosure: C.S.T. reports receiving research funding from Janssen and AbbVie and honoraria from Janssen,

Pharmacyclics, and AbbVie. J.F.S. reports receiving research funding from AbbVie and Janssen and honoraria from AbbVie, Celgene, Genentech, Janssen, Roche, Takeda, and Sunesis. ■

REFERENCES

1. Condoluci A, Terzi di Bergamo L, Langerbeins P, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. *Blood*. 2020;135(21):1859-1869.
2. International CLL-IPi working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPi): a meta-analysis of individual patient data. *Lancet Oncol*. 2016;17(6):779-790.
3. Abrisqueta P, Pereira A, Rozman C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. *Blood*. 2009;114(10):2044-2050.
4. Best OG, Gardiner AC, Davis ZA, et al. A subset of Binet stage A CLL patients with *TP53* abnormalities and mutated *IGHV* genes have stable disease. *Leukemia*. 2009;23(1):212-214.
5. Tam CS, Shanafelt TD, Wierda WG, et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. *Blood*. 2009;114(5):957-964.
6. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. *Blood*. 2018;131(25):2745-2760.
7. Mato AR, Barrientos JC, Ghosh N, et al. Prognostic testing and treatment patterns in chronic lymphocytic leukemia in the era of novel targeted therapies: results from the InformCLL Registry. *Clin Lymphoma Myeloma Leuk*. 2020;20(3):174-183.
8. Wierda WG, Byrd JC, Abramson JS, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 4.2020, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2020;18(2):185-217.
9. Herling CD, Cymbalista F, Groß-Ophoff-Müller C, et al. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial [published online ahead of print 18 February 2020]. *Leukemia*. doi:10.1038/s41375-020-0747-7.
10. Langerbeins P, Bahlo J, Rhein C, et al. The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. *Future Oncol*. 2015;11(13):1895-1903.

DOI 10.1182/blood.2020005426

© 2020 by The American Society of Hematology